Nuclear WATP or METTL3 downregulation has been linked to NASH (6, 7), and hepatic Wtap or Mettl3 deletion enhances liver damage, nonalcoholic fatty liver disease, and HCC initiation (6, 7, 27), whereas WTAP and METTL3 are abnormally elevated in HCC (13, 14), promoting HCC progression. The gene discussed is WTAP; the disease is metabolic dysfunction-associated steatohepatitis.